Loading...
Loading...
GPCR| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 45.8M |
| Operating I/L | -45.8M |
| Other Income/Expense | 12.0M |
| Interest Income | 0.0M |
| Pretax | -33.9M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -34.0M |
Structure Therapeutics Inc. is a clinical stage global biopharmaceutical company specializing in the development and delivery of novel oral therapeutics for chronic diseases with unmet medical needs. Its lead product candidate, GSBR-1290, is an oral small molecule agonist targeting glucagon-like-peptide-1 receptor for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics for pulmonary and cardiovascular diseases, including ANPA-0073 targeting apelin receptor for idiopathic pulmonary fibrosis and pulmonary arterial hypertension, and LTSE-2578, an oral small molecule lysophosphatidic acid 1 receptor antagonist for idiopathic pulmonary fibrosis treatment.
